Complexa is a clinical stage platform fibrosis and inflammation biopharmaceutical company researching and developing highly selective and reversible endogenous human cell signaling technologies targeting orphan diseases. Unique and profound to the Company is the ability of its technology to not only halt, but to reverse disease related fibrosis. The Company’s lead product CXA-10 has completed human safety and proof of target engagement studies and will begin Phase 2 trials for Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH) in mid-2016. A Phase 1B/2A program in Sickle Cell Disease and Sickle Cell Crisis is also planned for 2016. Complexa has over 100 published studies involving its technology covering many disease models from various international academic and industry collaborations. Complexa’s nitro and keto-fatty-acid anti-inflammatory human cell signaling technology stems from Nobel Prize winning research and a top 10 cited scientist in the field of biochemistry and pharmacology. The Company is led by highly experienced and prominent serial entrepreneurs in the healthcare industry.